Modulatory effect of raloxifene and estrogen on the metabolic action of growth hormone in hypopituitary women

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 5, 2010, Pages 2099-2106

  Birzniece, Vita ^a   Meinhardt, Udo ^a,e   Gibney, James ^a,f   Johannsson, Gudmundur ^a,g   Baxter, Robert C ^c   Seibel, Markus J ^d   Ho, Ken K Y ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Padiatrisch Endokrinologisches Zentrum Zurich   (Switzerland)

^f ADELAIDE AND MEATH HOSPITAL   (Ireland)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; GROWTH HORMONE; LEUCINE; RALOXIFENE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; HUMAN GROWTH HORMONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BIOSYNTHESIS; CALORIMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; ENERGY EXPENDITURE; ESTROGEN ACTIVITY; FEMALE; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE ACTION; HUMAN; HYPOPITUITARISM; METABOLISM; OXIDATION; PRIORITY JOURNAL; PROTEIN METABOLISM; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; ADULT; BLOOD; DRUG COMBINATION; ESTROGEN THERAPY; MIDDLE AGED; RANDOMIZATION;

ADULT; CALORIMETRY, INDIRECT; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LEUCINE; MIDDLE AGED; RALOXIFENE; RANDOM ALLOCATION; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 77952761674     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2743     Document Type: Article

References (28)

1. Jørgensen JO, Pedersen SA, Thuesen L, Jørgensen J, Ingemann-Hansen T, Skakkebaek NE, Christiansen JS 1989 Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1:1221-1225
2. Hoffman DM, O'Sullivan AJ, Freund J, Ho KK 1995 Adults with growth hormone deficiency have abnormal body composition but normal energy metabolism. J Clin Endocrinol Metab 80:72-77
3. Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M, Ho KK 2001 Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. Am J Physiol Endocrinol Metab 281:E1191-E1196 (Pubitemid 34001193)
4. Burt MG, Gibney J, Hoffman DM, Umpleby AM, Ho KK 2008 Relationship between GH-induced metabolic changes and changes in body composition: a dose and time course study in GH-deficient adults. Growth Horm IGF Res 18:55-64
5. de Paula FJ, Góis-Júnior MB, Aguiar-Oliveira MH, Pereira Fde A, Oliveira CR, Pereira RM, Farias CT, Vicente TA, Salvatori R 2009 Consequences of lifetime isolated growth hormone(GH) deficiency and effects of short-term GH treatment on bone in adults with a mutation in the GHRH-receptor gene. Clin Endocrinol (Oxf) 70:35-40
6. Snyder PJ, Biller BM, Zagar A, Jackson I, Arafah BM, Nippoldt TB, Cook DM, Mooradian AD, Kwan A, Scism-Bacon J, Chipman JJ, Hartman ML 2007 Effect of growth hormone replacement on BMD in adult-onset growth hormone deficiency. J Bone Miner Res 22: 762-770
7. Sneppen SB, Hoeck HC, Kollerup G, Sørensen OH, Laurberg P, Feldt-Rasmussen U 2002 Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults - an 18-month randomised, placebo-controlled, double blinded trial. Eur J Endocrinol 146:187-195 (Pubitemid 34162910)
8. Gibney J, Johannsson G, Leung KC, Ho KK 2005 Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women. J Clin Endocrinol Metab 90:3897-3903
9. O'Sullivan AJ, Crampton LJ, Freund J, Ho KK 1998 The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest 102:1035-1040
10. Ferrannini E 1988 The theoretical bases of indirect calorimetry: a review. Metabolism 37:287-301 (Pubitemid 18080935)
11. Matthews DE, Motil KJ, Rohrbaugh DK, Burke JF, Young VR, Bier DM 1980 Measurement of leucine metabolism in man from a primed, continuous infusion of L-[1-3C]leucine. Am J Physiol 238: E473-E479
12. Horber FF, Horber-Feyder CM, Krayer S, Schwenk WF, Haymond MW 1989 Plasma reciprocal pool specific activity predicts that of intracellular free leucine for protein synthesis. Am J Physiol 257: E385-E399
13. Hoffman DM, Pallasser R, Duncan M, Nguyen TV, Ho KK 1998 How is whole body protein turnover perturbed in growth hormone-deficient adults? J Clin Endocrinol Metab 83:4344-4349
14. Nissen SL, Miles JM, Gerich JE, Haymond MW 1982 Regulation of α-ketoisocaproate binding to albumin in vivo by free fatty acids. Am J Physiol 242:E67-E71
15. Gibney J, Wolthers T, Johannsson G, Umpleby AM, Ho KK 2005 Growth hormone and testosterone interact positively to enhance protein and energy metabolism in hypopituitary men. Am J Physiol Endocrinol Metab 289:E266-E271
16. Baxter RC, Martin JL 1986 Radioimmunoassay of growth hormone-dependent insulin like growth factor binding protein in human plasma. J Clin Invest 78:1504-1512
17. Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB 2008 Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 63:163-181
18. Dayspring T, Qu Y, Keech C 2006 Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia. Metabolism 55:972-979
19. Johansson H, Bonanni B, Mariette F, Cazzaniga M, Baglietto L, Guerrieri-Gonzaga A, Sandri MT, Luini A, Pelosi G, Decensi A 2006 Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer. Breast Cancer Res Treat 98:167-172
20. Attanasio R, Barausse M, Cozzi R 2003 Raloxifene lowers IGF-I levels in acromegalic women. Eur J Endocrinol 148:443-448 (Pubitemid 36527415)
21. Dimaraki EV, Symons KV, Barkan AL 2004 Raloxifene decreases serum IGF-I in male patients with active acromegaly. Eur J Endocrinol 150:481-487
22. Torrisi R, Baglietto L, Johansson H, Veronesi G, Bonanni B, Guerrieri-Gonzaga A, Ballardini B, Decensi A 2001 Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. Br J Cancer 85:1838-1841
23. Duschek EJ, de Valk-de Roo GW, Gooren LJ, Netelenbos C 2004 Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-I and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study. Fertil Steril 82:384-390
24. Eng-Wong J, Hursting SD, Venzon D, Perkins SN, Zujewski JA 2003 Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol Biomarkers Prev 12:1468-1473 (Pubitemid 38031751)
25. Juul A, Flyvbjerg A, Frystyk J, Müller J, Skakkebaek NE 1996 Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins-1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty. Clin Endocrinol (Oxf) 44:515-523
26. Ricort JM, Binoux M 2001 Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity. Endocrinology 142:108-113
27. Rechler MM, Clemmons DR 1998 Regulatory actions of insulin-like growth factor-binding proteins. Trends Endocrinol Metab 9:176-183
28. Muzumdar RH, Ma X, Fishman S, Yang X, Atzmon G, Vuguin P, Einstein FH, Hwang D, Cohen P, Barzilai N 2006 Central and opposing effects of IGF-I and IGF-binding protein-3 on systemic insulin action. Diabetes 55:2788-2796